Table 1.

Summary of Recommendations on Optimal Screening Strategies to Detect NAFLD.

Screening strategies	Guidelines
Routine screening	None
Screen high risk patients	AACE, Egyptian guidelines, AGA, KASL, APASL, ALEH, Catalan guidelines, BASL, CSG, EASL, BSG, JSG, DGVS, AAEH. (14)
Diabetes	AACE, Egyptian guidelines, AGA, KASL, APASL, ALEH, Catalan guidelines, BASL, CSG, EASL, BSG, JSG, DGVS, AAEH. (14)
Obesity	AACE, Egyptian guidelines, AGA, APASL, ALEH, Catalan guidelines, BASL, CSG, EASL, BSG, JSG, DGVS, AAEH. (13)
Metabolic syndrome	AACE, Egyptian guidelines, AGA, KASL, APASL, ALEH, BASL, CSG, EASL, BSG, JSG, DGVS, AAEH. (13)
Elevated transaminases	AACE, AGA, KASL, ALEH, CSG, BSG, DGVS. (7)
History of ischemic cardiovascular disease	BASL. (1)
History of arterial hypertension	DGVS. (1)
Recommend against screening, even in high-risk patients	AASLD, SBH. (2)
Did not mention	AISF, NICE-UK, AFEF, INASL. (4)

Abbreviations: AACE, American Association of Clinical Endocrinology; AAEH, Asociación Española para el Estudio del Hígado; AASLD, American Association for the Study of Liver Diseases; AFEF, French Association for the Study of the Liver; AGA, American Gastroenterology Association; AISF, Italian Association for the Study of the Liver; APASL, The Asian Pacific Association for the Study of the Liver; ALEH, Latin American Association for the study of the liver; BASL, Belgian Association for the Study of the Liver; BSG, British Society of Gastroenterology; CSG, Chinese Society of Gastroenterology; DGVS, German Society of Gastroenterology, Digestive and Metabolic Diseases; EASL, European Association for the Study of the Liver; JSG, Japanese Society of Gastroenterology; INASL, India National Association for the Study of the Liver; KASL, The Korean Association for the Study of the Liver; NICE, National Institute for Health and Care Excellence; SBH, Brazilian Society of Hepatology.